In a recent bid Agenus Inc. [AGEN] faced a contemporary bid of $3.57 yielding a -0.55% decline where 1.24 million shares have exchanged hands over the last week. AGEN amount got a fall by -1.79% or -$0.06 versus $3.63 at the end of the prior session. This change led market cap to move at 653.00M, putting the price 95.88% below the 52-week high and -36.68% above the 52-week low. The company’s stock has a normal trading capacity of 1.24 million shares while the relative volume is 1.10.
On 3, December 2020, Completion of Balstilimab BLA Filing Extended To 1H2021. According to news published on Yahoo Finance, Agenus to fulfill FDA feedback for six-month follow-up on late responders.
Analyst Birdseye View:
The most recent analyst activity for Agenus Inc. [NASDAQ:AGEN] stock was on April 22, 2019, when it was Initiated with a Buy rating from B. Riley FBR. Before that, on November 19, 2019, B. Riley FBR Recapitulated a Buy rating and elevated its amount target to $6. On October 28, 2016, H.C. Wainwright Downgrade a Neutral rating and plunged its price target on this stock from $10 to $5. On October 27, 2016, Maxim Group Reiterated a Buy rating. On March 11, 2016, Maxim Group Upgrade a Buy rating and increased its price target to $7. On December 16, 2015, Jefferies Initiated a Buy rating. On October 27, 2015, Maxim Group Downgrade a Hold rating. MLV & Co elevated its amount target by recapitulating a higher weight for this stock.
In the past 52 weeks of trading, this stock has oscillated between a low of $1.82 and a peak of $5.63. Right now, according to Wall Street analyst the average 12-month amount target is $8.00. At the most recent market close, shares of Agenus Inc. [NASDAQ:AGEN] were valued at $3.57.
Agenus Inc. [NASDAQ:AGEN] most recently reported quarterly sales of 79.89 billion, which represented growth of -25.60%. This publicly-traded organization’s revenue is $125,114 per employee, while its income is -$543,170 per employee. This company’s Gross Margin is currently 98.30%, its Pretax Margin is -440.53, and its Net Margin is -434.14.
It shows enduring liability to assets at 0.10 while looking for an extended time period.
Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 3.54 points at 1st support level, the second support level is making up to 3.44. But as of 1st resistance point, this stock is sitting at 3.77 and at 3.90 for 2nd resistance point.
Agenus Inc. [AGEN] reported its earnings at -$0.28 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.26/share signifying the difference of -0.02 and -7.70% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$0.28 calling estimates for -$0.27/share with the difference of -0.01 depicting the surprise of -3.70%.
Important Ratio’s To Watch
Meanwhile, turning our focus to liquidity, the Current Ratio for Agenus Inc. [NASDAQ:AGEN] is 0.90. Likewise, the Quick ratio is also the same, showing Cash ratio at 0.78. Now if looking for a valuation of this stock’s amount to sales ratio it’s 7.17.
The most recent insider trade was by INCYTE CORP, 10% Owner, and it was the sale of 0.14 million shares on Jun 17. INCYTE CORP, the 10% Owner, completed a sale of 72080.0 shares on Jun 16. On Jun 15, INCYTE CORP, 10% Owner, completed a sale of 0.38 million shares.